Literature DB >> 23262937

The utility and management of vaginal cytology after treatment for endometrial cancer.

Akiva P Novetsky1, Lindsay M Kuroki, L Stewart Massad, Andrea R Hagemann, Premal H Thaker, Matthew A Powell, David G Mutch, Israel Zighelboim.   

Abstract

OBJECTIVE: To estimate the accuracy of vaginal cytology in postoperative surveillance for detecting recurrent endometrial cancer and to estimate the optimal management of squamous abnormalities detected in this setting.
METHODS: This review included women who underwent hysterectomy for endometrial cancer between January 1, 2006, and December 31, 2010, and had at least one postoperative Pap test. Clinical and demographic data were collected and outcomes including abnormal vaginal cytology, results of colposcopic examination, and endometrial cancer recurrence were assessed. A Cox regression model to estimate the risk of abnormal cytology was created. Sensitivity, specificity, and negative and positive predictive values of detecting vaginal recurrences were calculated.
RESULTS: Four hundred thirty-three women contributed 2,378 Pap tests. At least one abnormal cytology result was found during follow-up of 55 (13%) women, representing 3% of all Pap tests. No recurrent endometrial cancers were diagnosed on the basis of isolated abnormal cytology. No cases of recurrent cancer were diagnosed in women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion (LSIL) Pap test results. In multivariable analysis, abnormal cytology was highly associated with prior postoperative radiation therapy (P<.001). The sensitivity, specificity, and positive and negative predictive values of an abnormal Pap test result in detecting a local recurrence are 40%, 87.9%, 7.3%, and 98.4%, respectively.
CONCLUSION: Colposcopy is not needed after a Pap test result read as atypical squamous cells of undetermined significance or LSIL. LEVEL OF EVIDENCE: III.

Entities:  

Mesh:

Year:  2013        PMID: 23262937      PMCID: PMC3864642          DOI: 10.1097/aog.0b013e31827499a9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  20 in total

Review 1.  The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients.

Authors:  W A A Tjalma; P A van Dam; A P Makar; D J Cruickshank
Journal:  Int J Gynecol Cancer       Date:  2004 Sep-Oct       Impact factor: 3.437

Review 2.  Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.

Authors:  Ritu Salani; Floor J Backes; Michael Fung Kee Fung; Christine H Holschneider; Lynn P Parker; Robert E Bristow; Barbara A Goff
Journal:  Am J Obstet Gynecol       Date:  2011-06       Impact factor: 8.661

3.  ACOG Practice Bulletin no. 109: Cervical cytology screening.

Authors: 
Journal:  Obstet Gynecol       Date:  2009-12       Impact factor: 7.661

4.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.

Authors:  R A Nout; V T H B M Smit; H Putter; I M Jürgenliemk-Schulz; J J Jobsen; L C H W Lutgens; E M van der Steen-Banasik; J W M Mens; A Slot; M C Stenfert Kroese; B N F M van Bunningen; A C Ansink; W L J van Putten; C L Creutzberg
Journal:  Lancet       Date:  2010-03-06       Impact factor: 79.321

5.  Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer.

Authors:  Lilie L Lin; Perry W Grigsby; Matthew A Powell; David G Mutch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

6.  Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.

Authors:  W K Huh; J M Straughn; A Mariani; K C Podratz; L J Havrilesky; A Alvarez-Secord; M A Gold; D S McMeekin; S Modesitt; A L Cooper; M A Powell; D G Mutch; S Nag; R D Alvarez; D E Cohn
Journal:  Int J Gynecol Cancer       Date:  2007-02-16       Impact factor: 3.437

7.  Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence.

Authors:  Patrick Petignat; Marjory Jolicoeur; Abdulaziz Alobaid; Pierre Drouin; Philippe Gauthier; Diane Provencher; David Donath; Thu Van Nguyen
Journal:  Gynecol Oncol       Date:  2005-12-28       Impact factor: 5.482

8.  Factors affecting risk of mortality in women with vaginal cancer.

Authors:  Chirag A Shah; Barbara A Goff; Kimberly Lowe; William A Peters; Christopher I Li
Journal:  Obstet Gynecol       Date:  2009-05       Impact factor: 7.661

9.  Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.

Authors:  Elmar A Joura; Sepp Leodolter; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Laura A Koutsky; Suzanne M Garland; Diane M Harper; Grace W K Tang; Daron G Ferris; Marc Steben; Ronald W Jones; Janine Bryan; Frank J Taddeo; Oliver M Bautista; Mark T Esser; Heather L Sings; Micki Nelson; John W Boslego; Carlos Sattler; Eliav Barr; Jorma Paavonen
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321

Review 10.  Follow-up after primary therapy for endometrial cancer: a systematic review.

Authors:  Michael Fung-Kee-Fung; Jason Dodge; Laurie Elit; Himu Lukka; Alex Chambers; Tom Oliver
Journal:  Gynecol Oncol       Date:  2006-03-23       Impact factor: 5.482

View more
  2 in total

Review 1.  Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models.

Authors:  Margaret I Liang; Emeline M Aviki; Jason D Wright; Laura J Havrilesky; Leslie R Boyd; Haley A Moss; Elizabeth L Jewell; David E Cohn; Sachin M Apte; Patrick F Timmins; Ronald D Alvarez; Jill Rathbun; Elizabeth Lipinski; Susan White; Dorimar Siverio-Minardi; Emily M Ko
Journal:  Gynecol Oncol       Date:  2020-01-06       Impact factor: 5.482

Review 2.  Major clinical research advances in gynecologic cancer in 2021.

Authors:  Jeong-Yeol Park; Jung-Yun Lee; Yoo-Young Lee; Seung-Hyuk Shim; Dong Hoon Suh; Jae-Weon Kim
Journal:  J Gynecol Oncol       Date:  2022-03       Impact factor: 4.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.